

## Cognitive decline associated with anticholinergics, benzodiazepines, and Z-drugs: findings from The Irish Longitudinal Study on Ageing (TILDA)

Frank Moriarty PhD<sup>a,b</sup>, George M Savva PhD<sup>c,d</sup>, Carlota M Grossi PhD<sup>d</sup>, Kathleen Bennett PhD<sup>e</sup>, Chris Fox MD<sup>f</sup>, Ian Maidment PhD<sup>g</sup>, Yoon K Loke MD<sup>f</sup>, Nicholas Steel PhD<sup>f</sup>, Rose Anne Kenny MD<sup>b</sup>, Kathryn Richardson PhD<sup>d</sup>

<sup>a</sup> HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland

<sup>b</sup> The Irish Longitudinal Study on Ageing, Trinity College Dublin

<sup>c</sup> Quadram Institute Bioscience, Norwich Research Park

<sup>d</sup> School of Health Sciences, University of East Anglia

<sup>e</sup> Division of Population Health Sciences, Royal College of Surgeons in Ireland

<sup>f</sup> Norwich Medical School, University of East Anglia

<sup>g</sup> School of Life and Health Sciences, Aston University

Corresponding author:

Frank Moriarty

HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland, Mercer Building, Noel Purcell Walk, Dublin 2, Ireland.

Email: [frankmoriarty@rcsi.ie](mailto:frankmoriarty@rcsi.ie)

Tel: 00-353-1-402-8575

**Principal Investigator statement:** The authors confirm that this was a secondary analysis of an established cohort study and therefore did not have a Principal Investigator.

**Running head:** Cognitive decline and medications

**Keywords:** Cognitive function; pharmacoepidemiology; anticholinergic medication; benzodiazepines; Z-drugs

Word count: 3,924

Abstract word count: 250

Table count: 3

Supplementary files: 1 figures, 6 tables

What is already known about this subject:

- Benzodiazepines, Z-drugs and drugs with anticholinergic activity have been linked with cognitive impairment.
- Most evidence is derived from observational studies of older people, with little research on middle-aged adults.
- Medication effects may be confounded by indication and these medications are often prescribed for early symptoms of prodromal stages of dementia.

What this study adds:

- In this study of adults aged 50 years and older, no consistent pattern of change in cognitive function was associated with the medication exposures tested, except for reduced recall among new users of anticholinergic medications.
- Further research in the younger-old adult population should be conducted to confirm these findings.

## **Abstract**

### **Aim**

To estimate the association between patterns of anticholinergic, benzodiazepine, and Z-drug medication use and change in cognitive function in middle-aged and older adults.

### **Method**

This prospective cohort study used data from the first three waves of The Irish Longitudinal Study on Ageing (TILDA), including community-dwelling adults aged  $\geq 50$  years followed for up to four years ( $n=7,027$ ).

Cognitive function was assessed using the Mini Mental State Examination, animal naming test, and word recall tests. Regular medication use was self-reported at baseline and follow-up interviews at two and four years. Pharmacy dispensing claims for a subset ( $n=2,905$ ) allowed assessment of medication use between interviews and cumulative dosage. Medication use at consecutive waves of TILDA was analysed in relation to change in cognitive function between waves.

### **Results**

Strongly anticholinergic medications (Anticholinergic Cognitive Burden scale 3), benzodiazepines, and Z-drugs were reported by 7.3%, 5.8% and 5.1% of participants respectively at any time during the study. Adjusting for potential confounders, new anticholinergic use between interviews was associated with change in recall score (-1.09, 95% confidence interval -1.64, -0.53) over 2 years compared to non-use, but not with MMSE (0.07; 95%CI -0.21, 0.34) or animal naming (-0.70; -1.43, 0.03). The pharmacy claims analysis was consistent with this finding. Other hypothesised associations were not supported.

### **Discussion**

Except for new use of anticholinergic medications, no other findings supported a risk of cognitive decline over 2-year periods in this middle-aged and older cohort. Patients and prescribers should weigh this potential risk against potential benefits of commencing anticholinergic medications.

## Introduction

Among the many physiological changes associated with the normal ageing process is a gradual decline in cognitive function over time.<sup>1</sup> However for some individuals, this cognitive decline may be accelerated and result in mild cognitive impairment or dementia. There are no disease-modifying treatments for dementia, and so it is important to identify modifiable risk factors for cognitive decline.

Medication use is one such potential risk factor. Older people are more susceptible to adverse drug effects due to physiological changes of ageing,<sup>2</sup> and often take many medications.<sup>3,4</sup> The prevalence of polypharmacy in older people appears to be rapidly increasing.<sup>5</sup> Drugs that target the brain or that cross the blood brain barrier and have off-target effects on the brain have received particular attention with respect to their potential impact on cognitive function.<sup>6</sup>

Anticholinergic medications are a diverse group of therapeutic agents, including certain antidepressants, antihistamines, drugs for urinary frequency, antipsychotics, and gastrointestinal antispasmodics. Anticholinergic effects include peripheral effects such as dry mouth and constipation, and central effects are known to include delirium and cognitive impairment.<sup>7-12</sup> Cholinergic transmission is important in the brain pathways involved in cognition and memory.<sup>13</sup> Older people may be particularly vulnerable to anticholinergic adverse effects on cognitive function due to age-related decreases in cholinergic neurons and receptors, and acetylcholine content of the brain.<sup>6</sup> Similar evidence in relation to cognitive impairment has been presented for benzodiazepines and Z-drug hypnotics prescribed for insomnia and anxiety.<sup>14,15</sup> These agents act on the gamma aminobutyric acid (GABA) A receptor, and with cholinergic transmission, GABAergic pathways are one of the most important in learning, memory, attention and executive function.<sup>16</sup>

Evidence in relation to long-term effects of anticholinergics and benzodiazepine and Z-drug hypnotics is primarily derived from observational studies,<sup>9,12,14,15,17</sup> and relationships observed from such studies are potentially biased due to selection bias or confounding by unmeasured factors. Confounding by indication is particularly likely, as many of these medications are used for conditions that affect cognitive function, such as insomnia, anxiety, and depression. These conditions are also common in the prodromal stages of dementia.<sup>18</sup> Most evidence of cognitive decline occurs in studies of the older population, where it is more likely these prescriptions were used for the early symptoms of prodromal stages of dementia. In addition, some previous studies have been cross-sectional or have included prevalent users of medications.<sup>7</sup> Such approaches are unable to determine direction of any causal relationship i.e. whether the medication led to cognitive impairment, or cognitive

impairment led to prescription of the medication, or whether a third factor causes both. Further, only evaluating either self-reported or prescribed/dispensed medications may lead to exposure misclassification.

Here we describe how scores on three common tests of cognitive function change over four years among a population-representative cohort of adults aged 50 and older Ireland, and how these changes are associated with new use, existing use or cessation of anticholinergic medications, benzodiazepines, and Z-drugs. By including middle-aged adults, it is less likely any associations detected are due to prescribing for symptoms of prodromal dementia. Our analysis is also strengthened by adjustment over time for conditions where these medications are indicated and being able to compare findings when medication exposures are recorded by self-report or by pharmacy dispensing claims.

## Methods

### Study design and participants

This is a cohort study and has been reported to adhere to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement for cohort studies.<sup>19</sup>

This study included 7,027 participants from The Irish Longitudinal Study on Ageing (TILDA), a nationally representative cohort study of community-dwelling adults aged 50 years and over in Ireland.<sup>20</sup> Participants are followed up every two years and at every assessment complete a computer-assisted personal interview (CAPI) with a trainer interviewer, a self-completion questionnaire, and, at waves 1 and 3, undergo a health assessment in a study centre or their own home. Detailed information on participants' social, economic, and health circumstances are collected. Ethical approval for TILDA was provided by the Faculty of Health Sciences Ethics Committee, Trinity College Dublin.

We included TILDA participants who had at least two consecutive waves of data collected from the first three waves of TILDA from 2009 to 2014 (i.e. Waves 1 and 2, or 2 and 3). TILDA did not recruit people with severe cognitive impairments such that they could not provide informed consent, and we further excluded those who stated that they had doctor diagnosed Alzheimer's disease, dementia, organic brain syndrome, senility, or serious memory impairment, or reported taking an anticholinesterase medication or memantine (indicating treatment for dementia).

### Outcomes

The outcome of interest was cognitive function. Three different cognitive assessments were conducted at all waves, the Mini Mental State Examination (MMSE), an animal naming test, and an assessment of recall. The MMSE is a global measure of cognitive function which comprises 30 items (covering visuospatial, language, concentration, working memory, memory recall, and orientation cognitive domains).<sup>21,22</sup> It was completed by participants during their health assessment at wave 1, and during the CAPI at waves 2 and 3. The animal naming test, included in the CAPI at all waves, is a measure of verbal fluency (which reflects language and executive function),<sup>23,24</sup> in which respondents are asked to name as many different animals as they can think of in one minute. The recall test is also conducted as part of the CAPI. The interviewer reads a list of ten words, and respondents are asked to recall as many words as possible immediately (scored out of 10). The same list is then read out again and participants are asked to recall the list again (scored out of 10). Finally after several minutes and further interview questions, the respondent is asked to recall all of the

words that they can (i.e. delayed recall, scored out of 10). The number of words named at both immediate recalls and the delayed recall were summed giving a total 'recall' score out of 30.

### ***Exposures***

Medications with anticholinergic effects, benzodiazepines and Z-drugs were ascertained independently from two sources, first by self-report at TILDA interviews and second through the Health Service Executive Primary Care Reimbursement Service (HSE-PCRS) pharmacy claims database.

During TILDA interviews, participants are asked to report "all medications that [they] take on a regular basis, like every day or every week", including prescription, non-prescription, over-the-counter, herbal and alternative medications, as well as vitamins. Up to twenty medications are recorded and classified by World Health Organisation Anatomical Therapeutic Classification (WHO-ATC) code ([https://www.whocc.no/atc\\_ddd\\_index/](https://www.whocc.no/atc_ddd_index/)). Strength and duration of use are not recorded during the interviews. Anticholinergic medications were defined based on the Anticholinergic Cognitive Burden (ACB) scale and included any drugs classified as having 'definite' anticholinergic effects according to the ACB scale (i.e. a score of 3).<sup>25</sup> Complete lists of exposure medications (anticholinergics, benzodiazepines and Z-drugs) and their corresponding ATC codes are included in eTable 1.

HSE-PCRS administrative data on pharmacy claims is available for the subset of TILDA participants eligible for the General Medical Services (GMS) scheme and who consented to this data linkage. The GMS scheme is a form of public health cover that provides health services including prescribed medications with a small co-payment.<sup>26</sup> Eligibility is based on household income and age, and so over represents older age groups and those with low incomes. Although only available for a subset of 2,905 participants, HSE-PCRS data includes details on the exact date of prescription, quantity and dose of all prescribed medication, with records prior to TILDA recruitment. This enables quantitative assessments of exposure based on the WHO Defined Daily Dosages (DDDs).

### ***Covariates***

We considered other characteristics which could confound the relationship between medication exposure and cognitive decline; these are fully described in eTable 2. These included demographics, self-reported incontinence, pain, and sleep difficulties, reported doctor-diagnosed eye, cardiovascular and other health conditions, as well as self-rated vision and hearing, screened depressive symptoms, and smoking status.

## Statistical methods

First, descriptive statistics were generated for baseline characteristics (i.e. measured at wave 1) for all included participants, and separately for those who had any anticholinergic, benzodiazepine, or Z-drug use during the study.

Analysis was conducted on the basis of 2-year exposure period i.e. from wave 1-2, and from wave 2-3. We calculated the 2-year change in the cognitive outcome measure over this period, and summarised this using mean and standard deviation by pattern of medication exposure. For each medication class, we considered four categories of exposure: none (no use at either wave), new (no use at baseline wave and use at follow-up wave), discontinued (use at baseline wave and no use at follow-up wave), and recurrent (use at both waves).

Assuming initiating the medications has an immediate negative impact on cognitive function, we hypothesised that (a) new use would result in greater cognitive decline relative to non-use and that (b) discontinued use would result in improved cognitive function relative to non-use. If prolonged use led to a further decline then we would observe (c) recurrent users having a greater cognitive decline compared to non-users. So to test these hypotheses each exposure group (new, discontinuing, recurrent) was compared to the non-user group.

As well as describing average change we estimated a linear regression model for change in each cognitive measure. All exposure variables were entered simultaneously. First these were adjusted for baseline wave (i.e. whether the period was wave 1-2 or 2-3), age at baseline wave, and sex, and then were adjusted for these and all other covariates listed in eTable 2. All covariates at baseline were adjusted for, as well as covariates at follow-up for potential indications for study drug classes (sleep difficulties, anxiety, depression, manic depression, other psychiatric conditions, incontinence, Parkinson's disease). Models were estimated with robust standard errors accounting for clustering of repeated exposure periods within participants.

As a secondary analysis we repeated the main analyses but with 'ACB3' exposure variables (new, discontinuing and recurring) sub-divided into antidepressant, urological, antipsychotic, and 'other' anticholinergic classes, adjusted for covariates and patterns of benzodiazepine and Z-drug use. We tested for equality of class effects i.e. whether the parameter estimate for new use was equal across antidepressants, urologicals, antipsychotics, and other anticholinergics. This was performed using the 'testparm' function in Stata using the 'equal' option.

We used a similar analytical approach using medication exposure based on pharmacy claims data. Dispensing was captured in the 90 days before individuals' CAPI at each wave, as well as in the



period between data collection and 90 days prior to the next wave. Exposure was classified as either non-use, new, discontinued, recurrent, or temporary use, as illustrated in eFigure 1. We also considered cumulative use among recurrent users based on the number of DDDs dispensed between baseline and follow-up, divided by quartiles into four groups, to investigate possible dose-response relationships.

We used Stata (version 14.0) for analysis. To account for the multiple outcomes tested, for final adjusted effect estimates we used the Benjamini-Hochberg procedure to control the false discovery rate (i.e. the proportion of rejected null hypotheses that are incorrect rejections) to less than 5%<sup>27</sup>

### ***Missing data***

An additional missing category was created for categorical covariates where the proportion of missing values was greater than 0.1%. For covariates with lower proportions of missing values, we used the last value carried forward, or if unavailable, first value carried back.

## Results

This study included 7,027 participants from TILDA, who contributed 13,161 2-year exposure periods. Selected descriptive characteristics are presented in Table 1 for all participants (with full details in eTable 3). Overall, the median age at baseline was 61 years (interquartile range 55 to 69 years) and the majority (55.6%) were female. The most prevalent self-reported doctor-diagnosed conditions were high cholesterol (38.3%), high blood pressure (35.5%) and arthritis (26.4%).

### Self-reported medication exposure

Anticholinergic use was reported at any time during the study by 510 (7.3%) participants, whilst benzodiazepine and Z-drug use was reported by 411 (5.8%) and 356 (5.1%) participants, respectively. Those reporting these medications were more often women (65-70% compared to 56% in the complete sample) and were around 5 years older (Table 1). Users reported a substantially higher prevalence of the conditions for which medications were indicated (e.g. sleep trouble more prevalent among those reporting benzodiazepines and Z-drugs, urinary incontinence and depression in those reporting strong anticholinergic use). Those reporting anticholinergic, benzodiazepine or Z-drug use were more likely to be disabled (20% reporting an activity of daily living disability compared to 7.5% in the complete sample).

Regarding patterns of use, 267 (2.0%) participants reported new anticholinergic use at wave 2 or 3, 184 (1.4%) reported discontinued use at wave 2 or 3, and 356 (2.7%) reported recurrent use between either waves 1 and 2 or waves 2 and 3. Similarly 204 (1.6%) reported new benzodiazepine use, 184 (1.4%) discontinued use, and 248 (1.9%) recurrent use. A total of 213 (1.6%) participants reported new Z-drug use, 133 (1.0%) reported discontinued use, and 200 (1.5%) recurrent use.

The mean (standard deviation) change in cognitive measure scores across each two-year period was 0.06 (1.76) for MMSE, -1.19 (5.98) for animal naming, and -0.04 (4.40) for recall.

### *Anticholinergics*

In short, no consistent pattern of decline or recovery in cognitive function was associated with any of the medication exposures we tested. In the regression models adjusted for all available patient characteristics (Table 2), new anticholinergic use was associated with a statistically significant additional decline in recall compared to no use (adjusted b coefficient -1.09, 95% confidence interval -1.64 to -0.53). Although we hypothesised that recurrent anticholinergic exposure would also be associated with reduced cognitive function, there was a relatively small decline which was not statistically significant (adjusted b coefficient -0.41, 95% CI -0.86 to 0.03). Similarly, new use was not

significantly associated with additional decline in MMSE (0.07, -0.21 to 0.34) or animal naming (-0.70, -1.43 to 0.03) compared to no use, nor were recurrent or discontinued use associated with incremental changes in cognitive function.

Cognitive decline did not differ significantly by anticholinergic drug class (eTable 4). However, new use of an antipsychotic (adjusted b coefficient -1.44, 95% CI -2.63 to -0.25) or a urological (-0.98, -1.87 to -0.09) was associated with the greatest magnitude of additional decline in recall relative to no use.

### ***Benzodiazepines/Z-drugs***

There was no evidence of a decline in cognitive function for recurrent use of benzodiazepines; the adjusted b coefficients (95% CIs) for MMSE, animal naming, and recall were -0.02 (-0.27 to 0.22); -0.09 (-0.70 to 0.51); and 0.40 (-0.16 to 0.97), respectively (Table 2). Similarly, associations for new and discontinued use with cognition did not reach statistical significance. No patterns of Z-drug use had a statistically significant association with change in cognition after adjustment for confounders and multiple testing. For example, the adjusted b coefficients and 95% CIs for recurrent use were -0.10 (-0.38 to 0.18); 0.26 (-0.41 to 0.94); and -0.22 (-0.82 to 0.38) for MMSE, animal naming, and recall, respectively (Table 2).

### **Pharmacy claims based exposure**

Characteristics of the 2,905 (41.3%) participants with linked pharmacy claims data are presented in eTable 5. Compared to the full TILDA sample, these participants tended to be older (mean age 67.5 years), have lower levels of educational attainment, and higher prevalence of both self-reported and doctor-diagnosed health issues.

Across each medication class, the majority ( $\geq 99.5\%$ ) of those with no record of being dispensed the medication class also did not report use. For those with no reported use, between 6.2% (anticholinergics) and 9.7% (benzodiazepines) had new, discontinued or recurrent use based on the dispensing data. Among those with new or recurrent dispensing who reported no use, the proportion who had regular use leading up to follow-up (dispensed in the 30 days before follow-up, with at least two further dispensings in the 6 months before follow-up) ranged from 44% (anticholinergics and benzodiazepines) to 52% (Z-drugs).

### ***Anticholinergics***

Similar to the main TILDA analysis, new anticholinergic use was associated with a change of -1.21 (95% CI -1.86 to -0.56) in cognitive recall relative to no use (Table 3), and in addition, recurrent use

was associated with a significant decline of smaller magnitude (-0.82, 95% CI -1.30 to -0.34). New use showed no significant associations with other outcomes (adjusted b coefficient 0.02, 95% CI -0.32 to 0.36 for MMSE, and -0.25, -1.02 to 0.52 for animal naming) nor did recurrent use (MMSE 0.17, -0.08 to 0.42; animal naming -0.48, -1.04 to 0.07). Discontinued use was not significantly associated with any of the three outcomes. When categorising recurrent anticholinergic use into quartiles of cumulative DDDs dispensed between baseline and follow-up (eTable 6), there was no statistically significant linear trend across cumulative anticholinergic dose in relation to change in cognitive function.

### ***Benzodiazepines/Z-drugs***

Again, as in the main analysis, there were no statistically significant changes in cognitive outcomes associated with patterns of benzodiazepine or Z-drug dispensings (Table 3). For example, recurrent use of benzodiazepines relative to no use had beta coefficients after adjustment of 0.24 (95% CI 0.03 to 0.45) for MMSE, 0.08 (-0.43 to 0.58) for animal naming, and 0.03 (-0.38 to 0.44) for recall.

There was a significant trend of increasing MMSE score across higher cumulative DDDs of benzodiazepines ( $p=0.001$ ), where for example the highest dose quartile (greater than 736 DDDs) was associated with a 0.71 (95% CI 0.25 to 1.16) relative increase in MMSE compared to no use (eTable 6).

## Discussion

We estimated the effect of strongly anticholinergic medications, benzodiazepines and Z-drugs on three tests of cognitive function, within a large longitudinal cohort of community dwelling adults strengthened through the linkage of pharmacy claims data. Although new anticholinergic use, and to some extent recurrent anticholinergic use, were associated with statistically significant reductions in recall scores over 2-year follow-up compared to non-use, there was no evidence of significant declines in MMSE or in verbal fluency as measured by animal naming. Although the magnitude of change was small, corresponding to approximately 0.2 SDs in recall score, and may not be clinically meaningful or detectable within an individual, a change of 0.2 SD does represent a more substantial effect at the population level. There was no evidence that new or recurrent use of benzodiazepine or Z-drug use was associated with any impairment of cognitive function in this population.

### Strengths and weaknesses of the study

Our study has several strengths and limitations. We included a large sample of representative community-dwelling adults, and included participants aged 50 years and older rather than many previous studies which have only considered older age groups (typically 65 years and older).<sup>28</sup> We simultaneously considered multiple medication classes for which there is evidence suggesting an effect on cognitive function and included a range of outcomes which captured multiple aspects of cognitive function. We also considered changes in exposure to medication among participants to estimate the marginal effect of commencing use or discontinuing use, providing stronger evidence of potential causality. We aimed to further strengthen the evidence for a potential causal claim by considering dose-response relationships and adjusting for likely indications for anticholinergics and hypnotics to reduce confounding by indication and protopathic bias. While we did not account for drugs with 'possible' anticholinergic effects (e.g. an ACB score of 1 or 2), those we did consider have established and clinically relevant anticholinergic effects, including delirium. Although anticholinergic scales differ on which medications they class as anticholinergic, they are typically consistent in classifying those with strong or definite anticholinergic activity.<sup>29</sup>

Our study was strengthened by using both self-reported medication use and pharmacy claims data to ascertain medication exposure, and capturing both prescribed and non-prescribed medications. Although self-reported medication use might underestimate exposure, and pharmacy claims data might over-estimate exposure, our findings were generally similar for both sources. Some individuals taking anticholinergics or hypnotics leading to cognitive decline may have been excluded from TILDA if not cognitively well at wave 1 recruitment as participants were required to provide written

informed consent, potentially biasing our study towards a null finding. Although our study period of four years is relatively long compared to some studies, it may be that even longer periods of cumulative exposure are required to observe an impact on cognitive function.<sup>30</sup>

## Comparison with other studies

A number of previous studies have reported anticholinergic drug use associated with decline in MMSE,<sup>10,31–33</sup> which was not replicated in the present study. These studies showed larger overall declines in MMSE among their study samples than observed here, for instance a 0.33 reduction associated with anticholinergic use versus non-use over two years in the Cognitive Function and Ageing Study.<sup>31</sup>

The relatively young population of our study, in comparison to previous research,<sup>10,15</sup> may also have contributed to a lack of observed association. A recent systematic review of longitudinal studies found that among studies with high methodological quality, there was an association between anticholinergic burden and dementia or cognitive impairment, except in middle-aged adults.<sup>28</sup> The lack of association in the two identified studies including adults aged 50-64 years was postulated to be due to lower dementia risk and greater baseline cholinergic brain activity than older adults. In the present study there is also a potential ceiling effect due to the high baseline MMSE scores.

A further explanation may be that the MMSE was administered in a different setting at wave 1 (at the health assessment by a trained nurse) compared to subsequent waves where it was administered during the CAPI by a trained interviewer in the participant's home, with the potential for measurement error and selection bias. However, we adjusted for baseline wave in our analysis, and our findings were consistent when restricted to wave 2 and 3 only (results not shown).

Most previous studies on benzodiazepine and Z-drug use report declines in cognitive function, although in most cases not statistically significant.<sup>34–38</sup> One of the studies with the largest magnitude of decline examined chronic benzodiazepine use (repeated use at baseline, 2-year follow-up and 4-year follow-up), suggesting a potential duration of use and/or cumulative dose effect.<sup>36</sup> However, we found no evidence of greater cognitive decline with greater DDDs of benzodiazepines dispensed. Consistent with our findings, recent studies suggest no or only modest associations between recurrent benzodiazepine use and incident dementia.<sup>15,39–42</sup> Non-randomised comparisons of benzodiazepine withdrawal versus continuation in studies of older adults have shown an association between withdrawal and improved cognitive function,<sup>43,44</sup> but a randomised trial including adults of any age on benzodiazepines found no difference in recall six months post withdrawal.<sup>45</sup>

## Study implications

Our findings suggest that among a wider middle-aged and older population, there might be a short-term impact on memory associated with new strong anticholinergic use but that this is unlikely to worsen if use is prolonged. Further research in the younger-old adult population on this issue should be conducted to confirm these findings. The lack of associations in our study could indicate lesser ability for anticholinergic medications to cross the blood brain barrier in this younger-old population or that protopathic bias is responsible for associations between anticholinergic medications and cognitive decline observed in older populations.

If our findings are confirmed, the potential risk of declines in memory should be communicated to people purchasing or being prescribed anticholinergic medicines so that, as with any medication class, the potential benefits and harms can be weighed up. For possible new users, prescribers should consider alternative therapeutic options, including non-pharmacological treatments.

Although risks of recurrent use of anticholinergics were not supported by our findings, prescribers may wish to consider ongoing need and potential for deprescribing given other published evidence on the impact of anticholinergics on cognitive decline in older ages with prolonged exposure.<sup>10,31-33</sup>

Research on the cognitive effects of anticholinergics and hypnotics has been predominantly observational, and causal inference is complicated by the extremely close links between illness and medication exposure. Future interventional studies should consider the cognitive effects of deprescribing anticholinergics, benzodiazepines, or Z-drugs compared to continuation of these agents. Such studies would provide stronger evidence to inform clinician and patient decisions to continue these medications.

## **Acknowledgement**

We wish to acknowledge all of the participants in The Irish Longitudinal Study on Ageing (TILDA), and the Health Service Executive Primary Care Reimbursement Service (HSE-PCRS) for providing access to the administrative pharmacy claims data used in this study.

## **Conflict of interest statement**

The authors declare that they have no competing interests, other than IM has received personal fees for guest lectures and to support travel from Astellas Pharmaceuticals; YL reports personal fees from Thame Pharmaceuticals, NC and CF have received grants and personal fees from Astellas Pharmaceuticals.

## **Funding information**

This work was supported by the UK Alzheimer's Society [AS-PG-2013-017]. Funding for TILDA is provided by the Irish Government, the Atlantic Philanthropies, and Irish Life.

## **Data availability statement**

The data that support the findings of this study are available from TILDA, with further details on access available at <https://tilda.tcd.ie/data/accessing-data/>.

## **Author contributions**

GS, CG, KB, CF, IM, YL, NS, RAK, and KR conceived the study, FM, GS, CG, RAK and KR designed the study, KB and RAK acquired the data, FM, GS and KR analysed and interpreted the data, FM drafted the manuscript and all authors were involved in the critical revision of this.



## References

1. Deary IJ, Corley J, Gow AJ, et al. Age-associated cognitive decline. *Br Med Bull*. 2009;92(1):135-152. doi:10.1093/bmb/ldp033
2. Corsonello A, Pedone C, Incalzi R. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. *Curr Med Chem*. 2010;17(6):571-584. doi:10.2174/092986710790416326
3. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. *J Am Geriatr Soc*. 2006;54(10):1516-1523. doi:10.1111/j.1532-5415.2006.00889.x
4. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. *BMJ Open*. 2015;5(9):e008656. doi:10.1136/bmjopen-2015-008656
5. Gao L, Maidment I, Matthews FE, Robinson L, Brayne C. Medication usage change in older people (65+) in England over 20 years: Findings from CFAS I and CFAS II. *Age Ageing*. 2018;47(2):220-225. doi:10.1093/ageing/afx158
6. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. *Exp Gerontol*. 2003;38(8):843-853. doi:10.1016/S0531-5565(03)00133-5
7. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. *Clin Interv Aging*. 2009;4:225-233. <http://www.ncbi.nlm.nih.gov/pubmed/19554093>. Accessed December 3, 2018.
8. Risacher SL, McDonald BC, Tallman EF, et al. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. *JAMA Neurol*. 2016;332(7539):455-459. doi:10.1001/jamaneurol.2016.0580
9. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. *BMJ*. 2018;361:k1315. doi:10.1136/BMJ.K1315
10. Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. *Age Ageing*. 2014;43(5):604-615. doi:10.1093/ageing/afu096
11. Ness J, Hoth A, Barnett MJ, Shorr RI, Kaboli PJ. Anticholinergic medications in community-dwelling older veterans: Prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. *Am J Geriatr Pharmacother*. 2006;4(1):42-51. doi:10.1016/J.AMJOPHARM.2006.03.008
12. Gray SL, Anderson ML, Dublin S, et al. Cumulative Use of Strong Anticholinergics and Incident Dementia. *JAMA Intern Med*. 2015;175(3):401. doi:10.1001/jamainternmed.2014.7663
13. van Waarde A, Ramakrishnan NK, Rybczynska AA, et al. The cholinergic system, sigma-1 receptors and cognition. *Behav Brain Res*. 2011;221(2):543-554. doi:10.1016/j.bbr.2009.12.043
14. Gray SL, Dublin S, Yu O, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. *BMJ*. 2016;352:i90. doi:10.1136/bmj.i90
15. Penninkilampi R, Eslick GD. A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias. *CNS Drugs*. 2018;32(6):485-497. doi:10.1007/s40263-018-0535-3
16. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A Systematic Review of

- Amnestic and Non-Amnestic Mild Cognitive Impairment Induced by Anticholinergic, Antihistamine, GABAergic and Opioid Drugs. *Drugs Aging*. 2012;29(8):639-658. doi:10.1007/BF03262280
17. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. *Br J Clin Pharmacol*. 2015;80(2):209-220. doi:10.1111/bcp.12617
  18. Stella F, Radanovic M, Balthazar MLF, Canineu PR, De Souza LC, Forlenza O V. Neuropsychiatric symptoms in the prodromal stages of dementia. *Curr Opin Psychiatry*. 2014;27(3):230-235. doi:10.1097/YCO.000000000000050
  19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med*. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296
  20. Donoghue OA, McGarrigle CA, Foley M, Fagan A, Meaney J, Kenny RA. Cohort Profile Update: The Irish Longitudinal Study on Ageing (TILDA). *Int J Epidemiol*. August 2018. doi:10.1093/ije/dyy163
  21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198. <http://www.ncbi.nlm.nih.gov/pubmed/1202204>. Accessed December 3, 2018.
  22. Cameron J, Worrall-Carter L, Page K, Stewart S, Ski CF. Screening for mild cognitive impairment in patients with heart failure: Montreal Cognitive Assessment versus Mini Mental State Exam. *Eur J Cardiovasc Nurs*. 2013;12(3):252-260. doi:10.1177/1474515111435606
  23. Whiteside DM, Kealey T, Semla M, et al. Verbal Fluency: Language or Executive Function Measure? *Appl Neuropsychol Adult*. 2016;23(1):29-34. doi:10.1080/23279095.2015.1004574
  24. Aita SL, Beach JD, Taylor SE, Borgogna NC, Harrell MN, Hill BD. Executive, language, or both? An examination of the construct validity of verbal fluency measures. *Appl Neuropsychol Adult*. March 2018:1-11. doi:10.1080/23279095.2018.1439830
  25. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. *Aging health*. 2008;4(3):311-320. doi:10.2217/1745509X.4.3.311
  26. Sinnott S-J, Bennett K, Cahir C. Pharmacoepidemiology resources in Ireland—an introduction to pharmacy claims data. *Eur J Clin Pharmacol*. 2017;73(11):1449-1455. doi:10.1007/s00228-017-2310-7
  27. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B*. 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x
  28. Andre L, Gallini A, Montastruc F, et al. Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. *Eur J Clin Pharmacol*. August 2019. doi:10.1007/s00228-019-02744-8
  29. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. *BMC Geriatr*. 2015;15(1):31. doi:10.1186/s12877-015-0029-9
  30. Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. *BMJ*. 2012;345:e6231. doi:10.1136/BMJ.E6231
  31. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive

- impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. *J Am Geriatr Soc*. 2011;59(8):1477-1483. doi:10.1111/j.1532-5415.2011.03491.x
32. Shah RC, Janos AL, Kline JE, et al. Cognitive Decline in Older Persons Initiating Anticholinergic Medications. Forloni G, ed. *PLoS One*. 2013;8(5):e64111. doi:10.1371/journal.pone.0064111
  33. Moga DC, Abner EL, Wu Q, Jicha GA. Bladder antimuscarinics and cognitive decline in elderly patients. *Alzheimer's Dement Transl Res Clin Interv*. 2017;3(1):139-148. doi:10.1016/J.TRCI.2017.01.003
  34. DeAlberio MJ, McAvay GJ, Seeman T, Berkman L. Psychotropic drug use and cognitive decline among older men and women. *Int J Geriatr Psychiatry*. 1997;12(5):567-574. doi:10.1002/(SICI)1099-1166(199705)12:5<567::AID-GPS552>3.0.CO;2-V
  35. Hanlon JT, Horner RD, Schmadler KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. *Clin Pharmacol Ther*. 1998;64(6):684-692. doi:10.1016/S0009-9236(98)90059-5
  36. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: The epidemiology of vascular aging study. *J Clin Psychopharmacol*. 2002;22(3):285-293. doi:10.1097/00004714-200206000-00009
  37. Bourgeois J, Elseviers MM, Van Bortel L, Petrovic M, Vander Stichele RH. The impact of chronic benzodiazepine use on cognitive evolution in nursing home residents. *Hum Psychopharmacol Clin Exp*. 2015;30(2):85-93. doi:10.1002/hup.2456
  38. Zhang Y, Zhou X, Meranus DH, Wang L, Kukull WA. Benzodiazepine Use and Cognitive Decline in Elderly With Normal Cognition. *Alzheimer Dis Assoc Disord*. 2016;30(2):113-117. doi:10.1097/WAD.0000000000000099
  39. Richardson K, Mattishent K, Loke YK, et al. History of Benzodiazepine Prescriptions and Risk of Dementia: Possible Bias Due to Prevalent Users and Covariate Measurement Timing in a Nested Case-Control Study. *Am J Epidemiol*. 2019;188(7):1228-1236. doi:10.1093/aje/kwz073
  40. Grossi CM, Richardson K, Fox C, et al. Anticholinergic and benzodiazepine medication use and risk of incident dementia: A UK cohort study. *BMC Geriatr*. 2019;19(1). doi:10.1186/s12877-019-1280-2
  41. Baek YH, Lee H, Kim WJ, et al. Uncertain Association Between Benzodiazepine Use and the Risk of Dementia: A Cohort Study. *J Am Med Dir Assoc*. 2020;21(2):201-211. doi:10.1016/j.jamda.2019.08.017
  42. Hafdi M, Hoevenaer-Blom MP, Beishuizen CRL, Moll van Charante EP, Richard E, van Gool WA. Association of Benzodiazepine and Anticholinergic Drug Usage With Incident Dementia: A Prospective Cohort Study of Community-Dwelling Older Adults. *J Am Med Dir Assoc*. 2020;21(2):188-193. doi:10.1016/j.jamda.2019.05.010
  43. Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelley M. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. *Int J Geriatr Psychiatry*. 1992;7(2):89-93. doi:10.1002/gps.930070205
  44. Curran HV, Collins R, Fletcher S, Kee SCY, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: Effects on cognitive function, sleep, mood and quality of life. *Psychol Med*. 2003;33(7):1223-1237. doi:10.1017/S0033291703008213
  45. Oude Voshaar RC, Gorgels WJM, Mol AJJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: Three-condition, randomised controlled trial. *Br J Psychiatry*. 2003;182(JUNE):498-504. doi:10.1192/bjp.182.6.498

## Tables

**Table 1. Characteristics of TILDA participants by self-reported anticholinergic, benzodiazepine, and Z-drug use**

Characteristic at wave 1	Medication use at wave 1, 2 or 3							
	All (n=7,027)		ACB3 use (n=510)		Benzo use (n=411)		Z-drug use (n=356)	
	n	%	n	%	n	%	n	%
Women	3,906	55.6	333	65.3	286	69.6	247	69.4
Age (years), median IQR	61	55, 69	65	57, 72	66	59, 75	67	59, 74
Third level or higher education	2,229	31.7	128	25.1	81	19.7	83	23.3
Married	5,042	71.8	317	62.2	228	55.5	199	55.9
Employment								
Employed	2,742	39.0	92	18.0	65	15.8	50	14.0
Retired	2,397	34.1	220	43.1	170	41.4	177	49.7
Other	1,888	26.9	198	38.8	176	42.8	129	36.2
Incontinence*	865	12.3	161	31.6	82	20.0	72	20.2
CES-D, median IQR	3	1-8	6	2-13	9	3-18	7	3-15
Pain*								
None	4,564	64.9	223	43.7	171	41.6	146	41.0
Mild	722	10.3	52	10.2	37	9.0	41	11.5
Moderate	1,157	16.5	137	26.9	108	26.3	100	28.1
Severe	576	8.2	98	19.2	94	22.9	69	19.4
Trouble falling asleep								
Most of the time	742	10.6	84	16.5	109	26.5	126	35.4
Sometimes	1,698	24.2	154	30.2	142	34.5	102	28.7
Rarely or never	4,587	65.3	272	53.3	160	38.9	128	36.0
Disabilities								
Not disabled	6,296	89.6	379	74.3	301	73.2	263	73.9
IADL disability only	203	2.9	32	6.3	27	6.6	27	7.6
Any ADL disability	528	7.5	99	19.4	83	20.2	66	18.5
Smoker								
Never	3,137	44.6	203	39.8	154	37.5	139	39.0
Past	2,669	38.0	211	41.4	141	34.3	132	37.1
Current	1,221	17.4	96	18.8	116	28.2	85	23.9
Fair/poor vision or registered blind	611	8.7	71	13.9	65	15.8	43	12.1
Fair/poor hearing	944	13.4	88	17.3	87	21.2	56	15.7
<b>Most prevalent self-reported doctor-diagnosed conditions</b>								
High cholesterol	2,688	38.3	232	45.5	178	43.3	167	46.9
High blood pressure	2,496	35.5	238	46.7	189	46.0	168	47.2
Arthritis	1,857	26.4	233	45.7	166	40.4	160	44.9
Cataracts*	677	9.6	76	14.9	77	18.7	61	17.1
Osteoporosis	669	9.5	93	18.2	72	17.5	67	18.8
Asthma	624	8.9	70	13.7	64	15.6	40	11.2
<b>Self-reported doctor-diagnosed conditions where study drug classes are indicated</b>								
Parkinson's disease	33	0.5	11	2.2	9	2.2	3	0.8
Anxiety	334	4.8	75	14.7	80	19.5	45	12.6
Depression	376	5.4	86	16.9	74	18.0	49	13.8
Manic depression	27	0.4	14	2.7	11	2.7	5	1.4
Other psychiatric condition	136	1.9	40	7.8	34	8.3	22	6.2

\* Incontinence missing for 17 (0.2%), pain missing for 8 (0.1%), cataracts missing for 11 (0.2%)

**Table 2. Cognitive change at 2-year follow-up compared to baseline and self-reported anticholinergic, benzodiazepine, and Z-drug medication use in TILDA**

Medication usage	N	Baseline cognitive score mean (SD)	2-year cognitive change, mean (SD)	b (95% CI), age, sex, wave adjusted†	b (95% CI), fully adjusted‡
<i>Anticholinergic</i>					
<b>MMSE</b>					
None	10,863	28.65 (1.85)	0.06 (1.75)	0	0
New	221	27.90 (2.70)	0.07 (2.11)	0.02 (-0.25, 0.30)	0.07 (-0.21, 0.34)
Discontinued	165	27.82 (2.72)	0.12 (2.00)	0.11 (-0.19, 0.40)	0.15 (-0.15, 0.45)
Recurrent	312	28.02 (2.24)	-0.03 (1.84)	-0.04 (-0.22, 0.13)	0.00 (-0.18, 0.19)
<b>Animal Naming</b>					
None	12,260	20.53 (6.60)	-1.18 (6.01)	0	0
New	265	19.37 (7.03)	-1.91 (5.96)	-0.68 (-1.40, 0.05)	-0.70 (-1.43, 0.03)
Discontinued	181	18.60 (6.75)	-0.60 (5.61)	0.52 (-0.31, 1.34)	0.47 (-0.37, 1.31)
Recurrent	349	19.07 (6.40)	-1.23 (5.25)	-0.09 (-0.58, 0.39)	-0.13 (-0.63, 0.36)
<b>Recall</b>					
None	12,202	20.04 (5.02)	0.00 (4.37)	0	0
New	259	18.65 (5.59)	-1.14 (4.54)	-1.09 (-1.64, -0.53)	-1.09 (-1.64, -0.53)*
Discontinued	177	18.57 (5.50)	-0.47 (4.78)	-0.42 (-1.13, 0.29)	-0.47 (-1.19, 0.25)
Recurrent	347	17.94 (5.36)	-0.49 (4.82)	-0.42 (-0.86, 0.01)	-0.41 (-0.86, 0.03)
<i>Benzodiazepine</i>					
<b>MMSE</b>					
None	11,021	28.64 (1.87)	0.05 (1.74)	0	0
New	176	27.88 (2.20)	0.16 (2.11)	0.12 (-0.20, 0.43)	0.11 (-0.20, 0.42)
Discontinued	155	27.70 (2.73)	0.28 (2.24)	0.27 (-0.08, 0.62)	0.27 (-0.07, 0.62)
Recurrent	209	27.78 (2.38)	-0.06 (1.96)	-0.07 (-0.32, 0.17)	-0.02 (-0.27, 0.22)
<b>Animal Naming</b>					
None	12,433	20.56 (6.63)	-1.19 (6.01)	0	0
New	202	17.66 (5.97)	-0.34 (5.48)	1.02 (0.26, 1.79)	0.90 (0.12, 1.67)
Discontinued	176	18.64 (6.17)	-1.55 (5.28)	-0.26 (-1.05, 0.54)	-0.43 (-1.25, 0.38)
Recurrent	244	18.07 (5.60)	-1.32 (5.18)	-0.02 (-0.61, 0.56)	-0.09 (-0.70, 0.51)
<b>Recall</b>					
None	12,368	20.04 (5.04)	-0.04 (4.38)	0	0
New	198	18.21 (5.18)	-0.32 (5.04)	-0.12 (-0.83, 0.58)	-0.11 (-0.81, 0.59)
Discontinued	177	18.02 (5.62)	0.02 (4.31)	0.26 (-0.37, 0.88)	0.20 (-0.43, 0.83)
Recurrent	242	17.52 (5.14)	0.07 (4.97)	0.36 (-0.19, 0.91)	0.40 (-0.16, 0.97)
<i>Z-drug</i>					
<b>MMSE</b>					
None	11,085	28.64 (1.87)	0.06 (1.74)	0	0
New	178	27.83 (2.52)	0.18 (2.28)	0.13 (-0.20, 0.46)	0.13 (-0.19, 0.46)
Discontinued	120	27.97 (2.37)	-0.44 (2.25)	-0.48 (-0.88, -0.08)	-0.41 (-0.79, -0.03)
Recurrent	178	27.66 (2.42)	-0.11 (1.90)	-0.13 (-0.41, 0.16)	-0.10 (-0.38, 0.18)
<b>Animal Naming</b>					
None	12,517	20.56 (6.61)	-1.18 (6.01)	0	0
New	209	18.00 (6.28)	-1.67 (5.57)	-0.41 (-1.16, 0.35)	-0.54 (-1.29, 0.21)
Discontinued	131	17.81 (6.30)	-1.26 (5.10)	-0.11 (-0.99, 0.77)	-0.18 (-1.06, 0.71)
Recurrent	198	17.39 (5.43)	-0.85 (5.50)	0.37 (-0.30, 1.04)	0.26 (-0.41, 0.94)
<b>Recall</b>					
None	12,456	20.03 (5.05)	-0.03 (4.39)	0	0
New	203	17.54 (5.22)	0.22 (4.52)	0.48 (-0.15, 1.11)	0.52 (-0.12, 1.15)
Discontinued	128	18.24 (5.07)	-0.30 (4.10)	-0.06 (-0.77, 0.66)	0.01 (-0.71, 0.72)
Recurrent	198	17.60 (5.05)	-0.53 (4.74)	-0.22 (-0.81, 0.38)	-0.22 (-0.82, 0.38)

† b coefficients shown are change relative to 'None' category.

# Adjusted for demographics, baseline wave, self-reported incontinence, pain, and sleep difficulties, reported doctor-diagnosed eye, cardiovascular and other health conditions, self-rated vision and hearing, screened depressive symptoms, and smoking status.

\* Fully-adjusted beta remaining statistically significant after controlling the false discovery rate to <5% (based on 27 tests)  
Use categorised as none (no use at either baseline or follow-up waves), new (no use at baseline and use at follow-up), discontinued (use at baseline and no use at follow-up) and recurrent (use at both baseline and follow-up waves).

**Table 3. Cognitive change at 2-year follow-up compared to baseline and pharmacy claims based anticholinergic, benzodiazepine, and Z-drug medication use in TILDA**

Medication usage	N	2-year cognitive change, mean (SD)	b (95% CI), age, sex, wave adjusted†	b (95% CI), fully adjusted†#
<i>Anticholinergic</i>				
<b>MMSE</b>				
None	3,240	0.02 (1.99)	0	0
New	180	0.02 (2.31)	-0.01 (-0.35, 0.34)	0.02 (-0.32, 0.36)
Discontinued	146	0.12 (2.03)	0.14 (-0.18, 0.47)	0.14 (-0.19, 0.47)
Recurrent	286	0.15 (2.17)	0.11 (-0.13, 0.35)	0.17 (-0.08, 0.42)
Temporary	337	0.08 (1.95)	0.04 (-0.17, 0.26)	0.05 (-0.17, 0.28)
<b>Animal Naming</b>				
None	3,769	-1.09 (5.75)	0	0
New	213	-1.43 (5.42)	-0.30 (-1.06, 0.46)	-0.25 (-1.02, 0.52)
Discontinued	163	-1.14 (5.18)	-0.13 (-0.94, 0.68)	-0.25 (-1.07, 0.57)
Recurrent	335	-1.43 (5.17)	-0.39 (-0.94, 0.16)	-0.48 (-1.04, 0.07)
Temporary	390	-1.22 (5.78)	-0.21 (-0.79, 0.36)	-0.24 (-0.84, 0.35)
<b>Recall</b>				
None	3,734	-0.13 (4.77)	0	0
New	211	-1.36 (4.55)	-1.24 (-1.87, -0.60)	-1.21 (-1.86, -0.56)*
Discontinued	161	-0.18 (4.63)	-0.01 (-0.73, 0.71)	-0.05 (-0.79, 0.68)
Recurrent	330	-0.94 (5.01)	-0.84 (-1.31, -0.38)	-0.82 (-1.30, -0.34)*
Temporary	384	-0.32 (4.74)	-0.23 (-0.73, 0.27)	-0.22 (-0.72, 0.29)
<i>Benzodiazepine</i>				
<b>MMSE</b>				
None	3,066	0.00 (1.95)	0	0
New	156	0.18 (2.60)	0.14 (-0.28, 0.56)	0.18 (-0.23, 0.60)
Discontinued	176	0.07 (2.07)	0.09 (-0.22, 0.39)	0.07 (-0.24, 0.38)
Recurrent	359	0.23 (2.13)	0.18 (-0.03, 0.38)	0.24 (0.03, 0.45)
Temporary	432	0.07 (2.11)	0.02 (-0.18, 0.22)	0.06 (-0.14, 0.26)
<b>Animal Naming</b>				
None	3,560	-1.16 (5.72)	0	0
New	171	-1.58 (5.48)	-0.40 (-1.26, 0.46)	-0.39 (-1.25, 0.47)
Discontinued	205	-0.85 (5.98)	0.31 (-0.55, 1.16)	0.11 (-0.76, 0.97)
Recurrent	434	-1.17 (5.13)	0.15 (-0.33, 0.62)	0.08 (-0.43, 0.58)
Temporary	500	-0.96 (5.80)	0.24 (-0.29, 0.77)	0.17 (-0.36, 0.70)
<b>Recall</b>				
None	3,519	-0.25 (4.77)	0	0
New	170	-0.51 (4.30)	-0.15 (-0.82, 0.51)	-0.13 (-0.81, 0.55)
Discontinued	202	-0.32 (4.54)	0.02 (-0.62, 0.65)	-0.04 (-0.70, 0.61)
Recurrent	430	-0.33 (4.78)	0.03 (-0.38, 0.43)	0.03 (-0.38, 0.44)
Temporary	499	-0.13 (5.09)	0.06 (-0.39, 0.51)	0.08 (-0.38, 0.53)
<i>Z-drug</i>				
<b>MMSE</b>				
None	3,385	0.04 (2.00)	0	0
New	143	0.31 (2.20)	0.24 (-0.13, 0.61)	0.24 (-0.14, 0.61)
Discontinued	98	-0.48 (2.11)	-0.51 (-0.93, -0.09)	-0.52 (-0.93, -0.10)
Recurrent	281	-0.16 (2.13)	-0.19 (-0.42, 0.04)	-0.16 (-0.40, 0.07)
Temporary	282	0.25 (2.01)	0.15 (-0.09, 0.40)	0.17 (-0.08, 0.42)
<b>Animal Naming</b>				
None	3,944	-1.13 (5.68)	0	0
New	169	-1.09 (5.44)	0.19 (-0.66, 1.04)	0.17 (-0.69, 1.03)
Discontinued	116	-0.73 (5.79)	0.45 (-0.62, 1.53)	0.52 (-0.56, 1.60)
Recurrent	325	-1.14 (5.47)	0.03 (-0.52, 0.57)	-0.05 (-0.60, 0.50)
Temporary	316	-1.41 (5.94)	-0.31 (-0.98, 0.37)	-0.29 (-0.97, 0.39)
<b>Recall</b>				
None	3,907	-0.25 (4.78)	0	0
New	166	-0.79 (4.63)	-0.46 (-1.20, 0.28)	-0.55 (-1.30, 0.20)
Discontinued	115	-0.50 (5.46)	-0.11 (-1.11, 0.89)	-0.19 (-1.18, 0.80)
Recurrent	319	-0.11 (4.55)	0.31 (-0.15, 0.77)	0.29 (-0.18, 0.77)

---

Temporary	313	-0.10 (4.74)	0.11 (-0.41, 0.63)	0.05 (-0.48, 0.59)
-----------	-----	--------------	--------------------	--------------------

---

† b coefficients shown are change relative to 'None' category.

# Adjusted for demographics, baseline wave, self-reported incontinence, pain, and sleep difficulties, reported doctor-diagnosed eye, cardiovascular and other health conditions, self-rated vision and hearing, screened depressive symptoms, and smoking status.

\* Fully-adjusted beta remaining statistically significant after controlling the false discovery rate to <5% (based on 36 tests)

Use categorised as none (no use from 90 days pre-baseline interview to follow-up), new (no use in 90 days pre-baseline and use between baseline and follow-up), discontinued (use in 90 days pre-baseline and no use in 90 days pre-follow-up interview) recurrent (use in both 90 days pre-baseline and 90 days pre-follow-up interview), and temporary (use between waves but not in the 90 days before either wave).